Genzyme Sues To Stop Generic Leukemia Treatment

Law360, New York (July 30, 2012, 7:38 PM EDT) -- Genzyme Corp. filed a lawsuit in New Jersey on Friday seeking to block specialty pharmaceutical company Abon Pharmaceuticals LLC's plans to develop a generic version of Genzyme’s injectable leukemia chemotherapy drug Clolar.

Genzyme says Abon — a small drug development company specializing in drug delivery research and product development — has filed an Abbreviated New Drug Application with the U.S. Food and Drug Administration for a treatment that infringes U.S. Patent Number 5,661,136, licensed to Genzyme co-plaintiff Southern Research Institute. Abon has denied the validity of...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.